Your browser does not support iframes.
Asthma accounts for a quarter of a million deaths annually worldwide. In the US, asthma accounted for almost 13 million missed school days, and more than 10 million missed work days. The economic and societal burden is immense.According to the WHO, an additional 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people die of COPD each year - the fifth leading cause of death globally. The WHO expects COPD to become the world’s third-leading cause of death by 2030.
Asthma is manageable. There are two key issues, and this is where Teva is focused. They are 1) treatment adherence and compliance, and 2) treating asthma when it is not controlled despite the use of optimal therapy.We are a major player in the treatment of respiratory disorders. We are developing new treatment options for patients based on the combination of our integrated strengths in specialty medicines (including both small molecules and biologics), device platforms and generics. This is creating a broad pipeline of intuitive, effective and accessible treatment options for patients, doctors and healthcare providers.
Adherence is a major issue in the effective management of asthma and chronic obstructive pulmonary disease (COPD). Research tells us that some 50-70% of patients do not adhere to their treatment. Moreover, many patients have multiple devices for different parts of their treatment (maintenance and rescue therapies). This adds to the complexity that patients face. Patients experience difficulties with the use of their inhalers, and incorrect inhaler use is directly linked to the effectiveness and stability of their asthma and COPD management. Improper inhaler use can result in increased exacerbation (acute attacks) of asthma or COPD requiring emergency care.Our approach to effective treatment management is the development of a new inhaler device platform for use in both maintenance and rescue therapies. This platform has been designed to be simple and intuitive. A patient simply opens, inhales and closes the device. This device is designed to deliver the needed dose simply by inhaling without the need to coordinate activation of the device while taking a breath – a major cause of treatment failure. This new delivery platform is designed to offer patients better control of their asthma and COPD, and may result in improved compliance.
10% of the world’s 300 million people suffer from uncontrolled asthma despite optimized therapy. This leads to reduced lung function, nocturnal symptoms, activity limitation and exacerbation. 7% of these patients are hospitalized overnight due to acute attacks. In the EU alone, this costs $20B a year. There are currently no approved treatments directly targeting the cause of exacerbation.Asthma exacerbation is often caused by the proliferation of pro-inflammatory cells called eosinophils. A protein known as Interleukin-5 (IL-5) plays a key role in the production and role of eosinophils. We are developing a monoclonal antibody (biologic treatment), known as Reslizumab, that specifically targets IL-5 in order to interrupt the production of these cells that may lead to asthma exacerbations.Reslizumab has completed an extensive clinical development program in eosinophilic asthma. We plan to submit this product for marketing approval. Discover more about Reslizumab’s clinical development program >